Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 586 to 600 of 2208 results for guidelines

  1. NICE-wide topic prioritisation: the manual (PMG46)

    This manual sets out the process for how new guidance topics and updates to existing NICE guidance are identified, prioritised and routed at NICE, and the decision-making framework used by the NICE prioritisation board

  2. Pancreatic cancer (QS177)

    This quality standard covers diagnosis of pancreatic cancer and management of pancreatic ductal adenocarcinoma in adults aged over 18. This quality standard describes high-quality care in priority areas for improvement. It does not cover national initiatives, such as cancer screening or audit.

  3. Diabetes: annual albumin creatinine test (IND111)

    This indicator covers the percentage of patients with diabetes who have a record of an albumin creatinine ratio (ACR) test in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  4. Oesophago-gastric cancer (QS176)

    This quality standard covers assessing and managing oesophago-gastric cancer in adults. It describes high-quality care in priority areas for improvement.

  5. Antimicrobials evaluation panel members

    Read the biographies for all members of the NICE antimicrobial evaluation committee.

  6. Bronchiolitis in children (QS122)

    This quality standard covers assessing, diagnosing and managing bronchiolitis in children. It describes high-quality care in priority areas for improvement.

  7. COVID-19 rapid guideline: renal transplantation (NG178)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guideline on renal replacement therapy and conservative management and for people with COVID-19 see our guideline on managing COVID-19.

  8. Looked-after children and young people (NG205)

    This guideline covers how organisations, practitioners and carers should work together to deliver high-quality care, stable placements and nurturing relationships for looked-after children and young people. It aims to help these children and young people reach their full potential and have the same opportunities as their peers.

  9. Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)

    Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making

  10. COVID-19 rapid guideline: vitamin D (NG187)

    This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.

  11. COVID-19 rapid guideline: severe asthma (NG166)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our guideline on managing COVID-19.

  12. Renal and ureteric stones: assessment and management (NG118)

    This guideline covers assessing and managing renal and ureteric stones. It aims to improve the detection, clearance and prevention of stones, so reducing pain and anxiety, and improving quality of life.

  13. COVID-19 rapid guideline: delivery of radiotherapy (NG162)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  14. Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

    Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.

  15. Vaccine uptake in under 19s (QS145)

    This quality standard covers increasing vaccine uptake among children and young people aged under 19 in groups and settings that have low immunisation coverage. It describes high-quality care in priority areas for improvement.